Dr. Reddy’s Laboratories Ltd (REDY)

4,400.00
+43.80(+1.01%)
  • Volume:
    307,956
  • Bid/Ask:
    4,400.00/4,404.00
  • Day's Range:
    4,354.25 - 4,414.80

REDY Overview

Prev. Close
4,356.2
Day's Range
4,354.25-4,414.8
Revenue
226.23B
Open
4,375
52 wk Range
3,654-4,931.05
EPS
186.45
Volume
307,956
Market Cap
731.96B
Dividend (Yield)
30.00
(0.68%)
Average Volume (3m)
433,650
P/E Ratio
23.40
Beta
0.22
1-Year Change
-4.9%
Shares Outstanding
166,051,752
Next Earnings Date
02 Feb 2023
What is your sentiment on Dr. Reddy’s Labs?
or
Market is currently closed. Voting is open during market hours.

Dr. Reddy’s Laboratories Ltd News

Dr. Reddy’s Laboratories Ltd Company Profile

Dr. Reddy’s Laboratories Ltd Company Profile

Employees
24795
Market
India
  • Type:Equity
  • Market:India
  • ISIN:INE089A01023
  • S/N:DRREDDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
  • sell Target 4100
    0
    • sell Drreddy target 4200
      0
      • Monday rock
        0
        • today it's bearing
          0
          • today it's bearing
            0
            • will it touch its 5614 again in early days?
              0
              • Bear 🐻 signal
                0
                • it like satyam computers
                  1
                  • no it will go down.
                    0
                    • Keep accumulating from this level. A good SIP stock in good correction. Don't miss it
                      1